Tianyin Pharmaceutical 10-K 9 Dec 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 09, 2014	Dec. 31, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'TIANYIN PHARMACEUTICAL CO., INC.	'	'
Entity Central Index Key	'0001362718	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--06-30	'	'
Document Type	'10-K	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	29,432,791	'
Entity Public Float	'	'	$16

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$16,120,041	$26,827,008
Restricted cash	994,017	4,536,000
Accounts receivable, net of allowance for doubtful accounts of $102,401 and $102,149 at June 30, 2014 and 2013, respectively	9,074,576	10,112,718
Inventory	3,841,712	6,036,014
Loan receivable	1,981,280	'
Deferred tax assets	1,180,510	'
Other current assets	376,504	313,320
Total current assets	33,568,640	47,825,060
Property and equipment, net	45,378,356	40,603,232
Intangibles, net	27,699,733	21,505,012
Goodwill	211,120	210,600
Total assets	106,857,849	110,143,904
Current liabilities:	'	'
Accounts payable and accrued expenses	1,592,459	1,352,560
Accounts payable - construction related	2,238,927	2,723,290
Short-term bank loans	4,547,200	5,929,200
Income tax payable	35,832	701,311
Other taxes payable	179,610	740,800
Other current liabilities	522,995	449,062
Total current liabilities	9,117,023	11,896,223
Total liabilities	9,117,023	11,896,223
Stockholders' equity:	'	'
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding at June 30, 2014 and 2013	'	'
Common stock, $0.001 par value, 50,000,000 shares authorized, 29,546,276 shares issued, 29,432,791 shares outstanding at June 30, 2014 and 29,496,276 shares issued, 29,382,791 shares outstanding at June 30, 2013	29,546	29,496
Additional paid-in capital	30,189,802	30,134,852
Treasury stock, 113,485 shares at cost	-135,925	-135,925
Statutory reserve	6,976,412	6,847,315
Retained earnings	50,193,258	50,967,308
Accumulated other comprehensive income	10,423,712	10,178,358
Total stockholders' equity	97,676,805	98,021,404
Noncontrolling interest	64,021	226,277
Total equity	97,740,826	98,247,681
Total liabilities and equity	$106,857,849	$110,143,904

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts	$102,401	$102,149
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	29,546,276	29,496,276
Common stock, shares outstanding	29,432,791	29,382,791
Treasury stock, shares	113,485	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Statements Of Operations [Abstract]	'	'
Sales	$46,555,021	$67,500,476
Cost of sales	30,674,098	41,496,812
Gross profit	15,880,923	26,003,664
Operating expenses	'	'
Selling expenses	7,800,507	11,442,664
General and administrative expenses	4,449,587	4,351,592
Research and development	946,300	894,995
Total operating expenses	13,196,394	16,689,251
Income from operations	2,684,529	9,314,413
Other income (expenses):	'	'
Interest income	165,533	162,563
Interest expense	-392,010	-437,897
Other expense	-3,070,795	'
Total other income (expenses)	-3,297,272	-275,334
Income (loss) before provision for income tax	-612,743	9,039,079
Provision for income tax	195,325	2,423,906
Net income (loss)	-808,068	6,615,173
Less: Net income (loss) attributable to noncontrolling interest	-163,115	-56,978
Net income attributable to Tianyin Pharmaceutical Co., Inc.	($644,952)	$6,672,151
Basic and diluted earnings per share	$0.03	$0.23
Weighted average number of common shares outstanding:	'	'
Basic and diluted	29,400,599	29,345,668

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Statements Of Comprehensive Income [Abstract]	'	'
Net income (loss)	($808,068)	$6,615,173
Other comprehensive income	'	'
Foreign currency translation adjustment	246,213	2,083,061
Total other comprehensive income	246,213	2,083,061
Total Comprehensive income (loss)	-561,855	8,698,234
Less: Comprehensive income (loss) attributable to the noncontrolling interest	-162,256	-51,749
Comprehensive income (loss) attributable to Tianyin Pharmaceutical Co., Inc.	($399,599)	$8,749,983

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net Income (loss)	($808,068)	$6,615,173
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	2,587,565	2,435,138
Deferred tax assets	-1,180,510	'
Provision for inventory obsolescence and markdown	1,527,483	159,123
Provision for bad debts	'	-14,004
Share-based payment	55,000	30,000
Changes in current assets and current liabilities:	'	'
Accounts receivable	1,065,075	1,400,397
Inventory	685,804	-201,972
Advance payments	'	645,923
Other current assets	-62,525	130,893
Accounts payable and accrued expenses	236,997	-264,388
Accounts payable - construction related	-491,994	1,935,150
Income tax payable	-668,443	-119,146
Other taxes payable	-564,060	225,356
Other current liabilities	72,959	-27,787
Net cash provided by operating activities	2,455,283	12,949,856
Cash flows from investing activities:	'	'
Addition to property and equipment	'	-1,704,154
Addition of Construction in progress	-6,450,737	-13,274,213
Additions to intangible assets - land use right	-6,973,301	-886,611
Loans receivable	-1,984,940	'
Acquisition of subsidiary	'	-207,285
Net cash used in investing activities	-15,408,978	-16,072,263
Cash flows from financing activities:	'	'
Trade notes payable	'	-4,703,775
Restricted cash	3,559,747	-908,865
Proceeds from short-term bank loans	4,555,600	10,300,470
Repayments of short-term bank loans	-5,954,820	-10,523,700
Net cash provided by (used in) financing activities	2,160,527	-5,835,870
Effect of foreign currency translation on cash	86,201	632,990
Net decrease in cash and cash equivalents	-10,706,967	-8,325,287
Cash and cash equivalents - beginning of year	26,827,008	35,152,295
Cash and cash equivalents - ending of year	16,120,041	26,827,008
Supplemental cash flow disclosure	'	'
Cash paid for interest	391,942	437,605
Income tax paid	$2,421,477	$2,543,053

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Treasury Stock [Member]	Preferred Stock [Member]	Additional Paid in Capital	Statutory Reserve	Retained Earnings	Accumulated other Comprehensive Income	Total Shareholder's Equity	Noncontrolling Interest
Beginning Balance at Jun. 30, 2012	$89,519,447	$29,446	($135,925)	'	$30,104,902	$6,120,143	$45,022,329	$8,100,526	$89,241,421	$278,026
Beginning Balance, Shares at Jun. 30, 2012	'	29,446,276	'	0	'	'	'	'	'	'
Net income	6,615,173	'	'	'	'	'	6,672,151	'	6,672,151	-56,978
Other comprehensive income:	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustment	2,083,061	'	'	'	'	'	'	2,077,832	2,077,832	5,229
Comprehensive income	8,698,234	'	'	'	'	'	'	'	8,749,983	-51,749
Common shares issued	30,000	50	'	'	29,950	'	'	'	30,000	'
Common shares issued, Shares	'	50,000	'	'	'	'	'	'	'	'
Statutory reserve	'	'	'	'	'	727,172	-727,172	'	'	'
Ending Balance at Jun. 30, 2013	98,247,681	29,496	-135,925	0	30,134,852	6,847,315	50,967,308	10,178,358	98,021,404	226,277
Ending Balance, Shares at Jun. 30, 2013	'	29,496,276	'	0	'	'	'	'	'	'
Net income	-808,068	'	'	'	'	'	-644,953	'	-644,953	-163,115
Other comprehensive income:	'	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustment	246,213	'	'	'	'	'	'	245,354	245,354	859
Comprehensive income	-561,855	'	'	'	'	'	'	'	-399,599	-162,256
Common shares issued, Shares	'	50,000	'	'	'	'	'	'	'	'
Common shares issued for services	55,000	50	'	'	54,950	'	'	'	55,000	'
Common shares issued for services, Shares	'	50,000	'	'	'	'	'	'	'	'
Statutory reserve	'	'	'	'	'	129,097	-129,097	'	'	'
Ending Balance at Jun. 30, 2014	$97,740,826	$29,546	($135,925)	'	$30,189,802	$6,976,412	$50,193,258	$10,423,712	$97,676,805	$64,021
Ending Balance, Shares at Jun. 30, 2014	'	29,546,276	'	0	'	'	'	'	'	'

Organization_and_Nature_of_Bus

Organization and Nature of Business	12 Months Ended
	Jun. 30, 2014
Organization and Nature Of Business [Abstract]	'
ORGANIZATION AND NATURE OF BUSINESS	'
	Note 1 – Organization and Nature of Business
	Tianyin Pharmaceutical Co., Inc. (the “Company” or “Tianyin”) was established under the laws of Delaware on August 20, 2002. The Company’s primary business is to research, manufacture, and sell pharmaceutical products through its subsidiaries in China. The accompanying consolidated financial statements include the financial statements of Tianyin Pharmaceutical Co., Inc. and its subsidiaries. The Company’s operating subsidiaries include Chengdu Tianyin Pharmaceutical., Tianyin Medicine Trading (TMT), Hengshuo Pharmaceutical (HSP) and Jiangchuan Pharmaceutical (JCM).
	In order to facilitate the relocation of Chengdu Tianyin’s business operation to Qionglai County and to secure land use rights for the relocation of manufacturing facilities as Qionglai Facility (QLF), Chengdu Tianyin needs to establish its presence at Qionglai County during the process of construction, while all operating subsidiaries of Chengdu Tianyin are registered outside of Qionglai. Therefore, the Company decided to acquire a pharmaceutical distribution company and registered it at Qionglai County as a subsidiary of Chengdu Tianyin. On August 29, 2012, Chengdu Tianyin entered into a Share Transfer Agreement (the "Agreement") with the two existing shareholders of Sichuan Hengshuo Pharmaceutical Co., Ltd (“Sichuan Hengshuo” or “HSP”). The share transfer was completed on November 30, 2012 by which Chengdu Tianyin acquired 100% ownership of HSP, a PRC company for a total consideration of $210,600 (RMB 1.3 million). As of June 30, 2014, the financial results of HSP are consolidated into the consolidated financial statements presented herein. The purchase price of $210,600 was assigned to goodwill as the net assets and operations of HSP were minimum at the date of acquisition (See Note 6).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Note 2 – Summary of Significant Accounting Policies
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America. The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
	Certain prior year amounts were reclassified to conform with current year presentation.
	Use of Estimates
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include valuation reserves for accounts receivable, inventory, estimated useful life and residual value of property, plant and equipment, recognition and measurement of deferred income tax and valuation allowance for deferred tax assets. Although these estimates are based on management’s knowledge of current events and actions management may undertake in the future, actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with original maturities of three months or less to be “cash equivalents”.
	Restricted Cash
	Restricted cash consists of cash equivalents used as collateral to secure short-term notes payable.
	Accounts Receivable
	Accounts receivable are recognized and carried at the original invoice amount less an allowance for any uncollectible amount. We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for potential bad debts if required.
	We determine whether an allowance for doubtful accounts is required by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also record a general allowance as necessary
	Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.
	The Company has not experienced any significant difficulty in collecting its accounts receivable in the past and is not aware of any financial difficulties being experienced by its major customers.
	Inventory
	Inventories consist of raw materials, packaging materials (which include ingredients and supplies) and finished goods. Inventory is stated at the lower of cost or market. Cost is determined using the weighted-average cost method. Provisions are made for excess, slow moving and obsolete inventory as well as inventory whose carrying value is in excess of net realizable value. Management continually evaluates the recoverability based on assumptions about customer demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory reserves or write-downs may be required that could negatively impact the Company’s gross margin and operating results. Inventory markdown allowance of $79,748 and zero were recorded at June 30, 2014 and 2013. Obsolete inventory of $1,447,735 and $159,123 were written-off in the year ended June 30, 2014 and 2013, respectively.
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets as follows:
	Vehicles		5 to 10 years
	Furniture, machinery and equipment		5 to 10 years
	Buildings and improvements		10 to 50 years
	Construction in progress primarily represents the renovation costs of plant, machinery and equipment and stated at cost less any accumulated impairment loss. Costs incurred are capitalized and transferred to property and equipment upon completion, at which time depreciation commences.
	Cost of repairs and maintenance is expensed as incurred. Gain or loss on disposal of property and equipment, if any, is recognized in the consolidated statements of operations.
	Impairment of Long-lived Assets
	In accordance with ASC Topic 360-10-35 “Accounting for the Impairment or Disposal of Long-Lived Assets,”, long-lived assets, such as property, plant and equipment and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable, or it is reasonably possible that these assets could become impaired as a result of technological or other industrial changes. The determination of recoverability of assets to be held and used is made by comparing the carrying amount of an asset to future undiscounted cash flows to be generated by the assets. The Company reviews the recoverability of its long-lived assets on a periodic basis in order to identify business conditions, which may indicate a possible impairment. The assessment for potential impairment is based primarily on the Company’s ability to recover the carrying value of its long-lived assets from expected future undiscounted cash flows. If the total of the expected future undiscounted cash flows is less than the total carrying value of the assets, a loss is recognized for the difference between the fair value (computed based upon the expected future discounted cash flows) and the carrying value of the assets.
	Intangible Assets
	Intangible assets comprised of approved drugs and rights to use land. Intangible asset is carried at cost, less related accumulated amortization. Approved drugs are separated into two groups: Traditional Chinese Medicine (TCM) and Non Traditional Chinese Medicine (NTCM). TCM which has an indefinite life are not being amortized and are subject to impairment test at least annually to determine if the carrying value of the asset is impaired. NTCM drugs are amortized on a straight-line basis over their estimated useful life of 10 years.
	Rights to use land with a finite useful life is being amortized on a straight line basis over its estimated useful life of 48 years.
	Goodwill
	The Company accounts for business acquisitions in accordance with ASC 805-10, which may result in the recognition of goodwill. Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations accounted for under the purchase method.
	Goodwill is not subject to amortization but will be subject to periodic evaluation for impairment. Goodwill is stated in the consolidated balance sheet at cost less accumulated impairment loss, if any. The Company reviews its goodwill for impairment annually or more frequently if indicators of impairment exist. The Company adopted an accounting standard update, commonly referred to as the step zero approach that allows it to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. For reporting units in which the qualitative assessment concludes it is more likely than not that the fair value is more than its carrying value, the amended guidance eliminates the requirement to perform further goodwill impairment test. For those reporting units where a significant change or event occurs, and where potential impairment indicators exist, the Company continues to utilize a two-step quantitative assessment to testing goodwill for impairment. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others (a) a significant decline in expected future cash flows; (b) a sustained, significant decline in stock price and market capitalization; (c) a significant adverse change in legal factors or in the business climate; (d) unanticipated competition; (e) the testing for recoverability of a significant asset group within a reporting unit; and (f) slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of these assets and could have a material impact on the consolidated financial statements. The goodwill test impairment consists of two steps. First, the identification of potential impairment is performed by comparing the fair value of the reporting unit to its carrying amount, including goodwill. Second, if there is impairment identified in the first step, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of goodwill. The Company has assessed its goodwill for impairment for the periods presented. There are no impairment charges related to goodwill for any of the fiscal periods presented.
	Impairment of Intangible Assets
	The Company applies the provisions of ASC Topic 350 which addresses how goodwill and other acquired intangible assets should be accounted for in financial statements. In this regard, the Company tests these intangible assets for impairment annually or more frequently if indicators of potential impairment are present. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value.
	The fair value is measured based on quoted market prices, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the year ended June 30, 2014, the Company applied a benchmark borrowing interest rate of 7.0% as the discount rate and recorded the impairment loss of $-0- related to intangible assets for the years ended June 30, 2014 and 2013, respectively.
	Revenue Recognition
	The Company derives its revenues primarily from sale of pharmaceutical products. In accordance with ASC Topic 605 “Revenue Recognition”, revenue should not be recognized until it is realized or realizable and earned. Revenues are considered to have been earned when the entity has substantially accomplished what it must do to be entitled to the benefits represented by the revenues. In this regard, the Company’s revenue is recognized when merchandise is received by customers or shipped by the Company pursuant to contractual terms of sales, title and risk of loss passes to the customers, sales amounts are fixed and determinable and the collectability is reasonably assured.
	Shipping and Handling Costs
	Shipping and handling costs billed to customers in related sales transactions are included in sales revenues and shipping expenses incurred by the Company are reported as a component of selling expenses. The shipping and handling expenses of $615,925 and $1,307,921 for the year ended June 30, 2014 and 2013, respectively, are reported in the Consolidated Statements of Operations as a component of selling expenses.
	Research and Development
	Research and development costs are expensed when incurred. Research and development costs for the years ended June 30, 2014 and 2013 were $949,300 and $894,995, respectively.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	A valuation allowance is provided to reduce the carrying amount of deferred tax assets if it is considered more likely than not that some portion, or all, of the deferred tax assets will not be realized.
	Value Added Taxes
	Under the Provisional Regulations of the PRC on Value Added Tax, the Company is responsible for collecting value added taxes on sales of products and to pay value added taxes on purchases of raw materials, which is then remitted to the central government. Sales and cost of sales are reported on a net basis excluding value added taxes.
	Fair Value of Financial Instruments
	The Company’s financial instruments include cash equivalents, accounts receivable, notes receivable, accounts payable, short-term debt and other financial instruments associated with the issuance of the common stock. The carrying values of cash equivalents, accounts receivable, notes receivable, and accounts payable approximate their fair value because of the short maturity of these instruments. The carrying amounts of the Company’s bank borrowings under its credit facility approximate fair value because the interest rates are reset periodically to reflect current market rates.
	The Company adopted ASC 820-10, “Fair Value Measurements.” ASC 820-10, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1: Observable inputs such as quoted prices in active markets;
	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	We have no financial assets or liabilities measured at fair value on a recurring basis
	Foreign Currency Translation and Transactions
	The Company has evaluated the determination of its functional currency based on the guidance in ASC Topic, “Foreign Currency Matters,” which provides that an entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment in which an entity primarily generates and expends cash.
	On its own, the Company raises financing in the U.S. Dollar, pays its own operating expenses primarily in the U.S. Dollar, paid dividends to its shareholders of common stock and expects to receive any dividends that may be declared by its subsidiaries in U.S. dollars.
	Therefore, it has been determined that the Company’s functional currency is the U.S. dollar based on the expense and financing indicators, in accordance with the guidance in ASC 830-10-85-5.
	The Company uses the United States dollar (“U.S. Dollar” or “US$” or “$”) for financial reporting purposes. The subsidiaries within the Company maintain their books and records in their respective functional currency, being the primary currency of the economic environment in which their operations are conducted. Assets and liabilities of a subsidiary with functional currency other than U.S. Dollar are translated into U.S. Dollars using the applicable exchange rates prevailing at the balance sheet date. Items on the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the Company’s financial statements are recorded as accumulated other comprehensive income.
	The exchange rates used to translate amounts in RMB into US Dollars for the purposes of preparing the condensed combined financial statements were as follows:
				June 30,	June 30,
				2014	2013
		Balance sheet items, except for shareholders’ equity items		RMB 1: US$0.1624	RMB 1: US$0.16200
	Amounts included in the statements of operations, comprehensive income, and cash flows for the years then ended		RMB 1: US$0.1627	RMB 1: US$0. 15945
	Shareholders’ equity items		Historical rate	Historical rate
Comprehensive Income
The Company has adopted ASC Topic 220-10, Reporting Comprehensive Income, which establishes rules for the reporting and display of comprehensive income, its components and accumulated balances. ASC 220-10 defines comprehensive income to include all changes in equity, including adjustments to minimum pension liabilities, accumulated foreign currency translation, and unrealized gains or losses on available-for-sale marketable securities, except those resulting from investments by stockholders and distributions to stockholders. Comprehensive income includes net income and the foreign currency translation gain, net of tax.
Share-Based Payment
The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
Earnings Per Share
In accordance with ASC 260, “Computation of Earnings Per Share” and EITF No. 03-6, “Participating Securities and the Two-Class Method under FASB Statement No. 128” (“EITF No. 03-6”), basic earnings per share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. The Company’s Series A redeemable convertible preferred shares are participating securities. Diluted earnings per share is calculated by dividing net income attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the year. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the convertible preferred shares (using the if-converted method) and ordinary shares issuable upon the exercise of outstanding share options (using the treasury stock method).
Recent Accounting Pronouncements
In April 2014, the FASB issued amendments to ASC Topic 205 “Presentation of Financial Statements” and ASC Topic 360 “Property, Plant and Equipment”. The amendments change the current requirements for reporting discontinued operations in Subtopic 205-20. It requires an entity to present, for each comparative period, the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability section, respectively, of the statement of financial position. This topic is effective for public entities for reporting periods beginning after December 15, 2014. An entity should not apply the amendments to a component classified as held for sale before the effective date even if the component of an entity is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company does not believe the adoption of the amendments to ASC 205 and ASC 360 will have a material effect on its consolidated financial statements.
There are no other new accounting pronouncements adopted or enacted during the year ended June 30, 2014 that had, or are expected to have, a material impact on the Company’s financial statements.

Inventory

Inventory	12 Months Ended
	Jun. 30, 2014
Inventory [Abstract]	'
INVENTORY	'
	Note 3 – Inventory
	Inventory at June 30, 2014 and 2013 consists of the following:
			June 30,		June 30,
			2014		2013
		Raw materials	$	690,355	$	748,296
		Packaging supplies		387,599		369,143
		Work in process		1,088,880		1,871,093
		Finished goods		1,674,878		3,047,482
		Total	$	3,841,712	$	6,036,014

Property_and_Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2014
Property and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	Note 4 – Property and Equipment
	Property and equipment at June 30, 2014 and 2013 consists of the following:
			June 30,		June 30,
			2014		2013
		Buildings	$	15,188,962	$	15,151,551
		Machinery and equipment		14,588,168		14,552,237
		Office equipment and furniture		102,236		101,984
		Vehicles		69,508		69,337
		Subtotal		29,948,874		29,875,109
		Less: Accumulated depreciation		7,127,561		5,350,377
				22,821,313		24,524,732
		Add: Construction in progress		22,557,043		16,078,500
		Total	$	45,378,356	$	40,603,232
	Depreciation expense for the fiscal years ended June 30, 2014 and 2013 was $1,767,232 and $1,631,191, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2014
Intangible Assets and Goodwill [Abstract]	'
INTANGIBLE ASSETS	'
	Note 5 – Intangible Assets
	Intangible assets at June 30, 2014 and 2013 consist of the following:
			June 30,		June 30,
			2014		2013
		Rights to use land	$	14,770,400	$	7,790,720
		Approved drugs		17,060,652		17,018,631
		Intangible assets		31,831,052		24,809,351
		Less: accumulated amortization		4,131,319		3,304,339
		Total	$	27,699,733	$	21,505,012
	Amortization expense for the fiscal years ended June 30, 2014 and 2013 was $820,333 and $803,947, respectively. The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2014
Intangible Assets and Goodwill [Abstract]	'
GOODWILL	'
	Note 6 – Goodwill
	On November 30, 2012, Chengdu Tianyin completed its acquisition of 100% equity interest in Sichuan Hengshuo for RMB 1.3 million, equivalent to $210,600. Goodwill, which is equal to the excess of cost over the fair value of assets acquired, has been recorded in conjunction with the acquisition. Goodwill is accounted for in accordance with ASC 350. The purchase price of $210,600 was assigned to goodwill as the net assets and operations of HSP were minimum at the date of acquisition.

Loan_Receivable

Loan Receivable	12 Months Ended
	Jun. 30, 2014
Loan Receivables [Abstract]	'
LOAN RECEIVABLE	'
	Note 7 – LOAN RECEIVABLE
	Loan receivable consists of following:
		Loan to an individual and guaranteed by a third party, collateralized by third party's machinery and equipment, bear interest at 50% above the bank standard rate and due on September 16, 2014. The loan was fully collected in September 19, 2014	$	812,000
		Loan to an unrelated company, bear interest at 50% above the bank standard rate and due on September 8, 2014. The loan was collateralized by the machinery and equipment of the company. The loan was fully collected in September 15, 2014.		1,169,280
		Total	$	1,981,280

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Jun. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	'
	Note 8 – Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consist of the following:
			June 30,		June 30,
			2014		2013
		Accounts payable	$	1,476,830	$	1,206,760
		Accrued expenses		115,629		145,800
		Total	$	1,592,459	$	1,352,560

Accounts_Payable_Construction_

Accounts Payable - Construction Related	12 Months Ended
	Jun. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
ACCOUNTS PAYABLE - CONSTRUCTION RELATED	'
	Note 9 – Accounts Payable – Construction Related
	Accounts payable – construction related consist of the following:
			June 30,		June 30,
			2014		2013
		Construction in progress payable	$	2,238,927	$	1,822,500
		Land use rights payable		-		900,790
		Total	$	2,238,927	$	2,723,790

ShortTerm_Bank_Loans

Short-Term Bank Loans	12 Months Ended
	Jun. 30, 2014
Short-Term Bank Loans [Abstract]	'
SHORT-TERM BANK LOANS	'
	Note 10 – Short-Term Bank Loans
	Short-term bank loans consist of the following:
			June 30,		June 30,
			2014		2013
		On September 19, 2012, the Company obtained a loan from China Huaxia Bank, the principal balance was paid in full on September 27, 2013. The interest is calculated using an annual fixed interest rate of 7.257% and paid monthly. The loan was guaranteed by a third party and the Company’s CEO, Dr. Jiang.		-	$	1,620,000
		On June 21, 2013, the Company obtained a loan from China CITIC Bank, which matures on December 21, 2013. The interest is calculated using an annual fixed interest rate of 6.44% and paid monthly. The loan was secured by the Company’s certificates of deposit, which included in the restricted cash on the Company’s balance sheet. The loan was paid in full in December 2013.		-	$	4,309,200
		On October 30, 2013, the Company obtained a loan from China CITIC Bank, which matures on October 30, 2014. The interest is calculated using an annual fixed interest rate of 7.20% and paid monthly. The loan was guaranteed by the Company’s CEO, Dr. Jiang.	$	4,547,200		-
		Total short-term bank loans	$	4,547,200	$	5,929,200

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
INCOME TAXES	'
	Note 11 – Income Taxes
	The Company's subsidiary, Raygere, is incorporated in the British Virgin Islands. Under the corporate tax laws of British Virgin Islands, it is not subject to tax on income or capital gain.
	The operating subsidiaries, Chengdu Tianyin, Tianyin Medicine Trading (TMT), HSP and JCM are all subject to 25% income tax rate. The tax write- offs and loss profit credit could only be applied to the individual subsidiaries of TPI.
	In July 2006, the FASB issued ASC 740 that clarifies the accounting for income taxes by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company did not recognize any benefits in the financial statements for the fiscal year ended June 30, 2014 and 2013.
	The comparison of income tax expense at the U.S. statutory rate of 35% in 2014 and 2013, to the Company’s effective tax is as follows:
			Fiscal Years ended
			June 30,
			2014			2013
		U.S. Statutory rate of 35%	$	(214,460	)	$	3,163,678
		Tax rate difference between China and U.S.		76,080			(903,778	)
		Change in valuation allowance		333,705			164,007
		Effective tax	$	195,325		$	2,423,907
	The provisions for income taxes are summarized as follows:
			Fiscal Years ended
			June 30,
			2014			2013
		Current	$	1,375,835		$	2,423,907
		Deferred		(1,678,222	)		(164,007	)
		Valuation allowance		497,712			164,007
		Total	$	195,325		$	2,423,907
	The tax effects of temporary differences that give rise to the Company’s net deferred tax asset as of June 30, 2014 and 2013 are as follows:
			June 30,			June 30,
			2014			2013
		Net operating loss carryforward	$	1,607,835		$	164,007
		Inventory markdown		19,937			-
		Accrued expenses		31,420			-
		Others		19,030			-
				1,678,222			164,007
		Less valuation allowance		(497,712	)		(164,007	)
		Deferred tax assets		1,180,510			-

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	Note 12 – Stockholders’ Equity
	The Company issued 50,000 shares of common stock incentive to the Company’s Chief Financial Officer each year during the year ended June 30, 2014 and 2013, respectively. These shares were valued at $55,000 and $30,000 for the shares issued during the year ended June 30, 2014 and 2013, respectively, and recorded in the statement of operations as compensation expense.

Statuary_Reserve

Statuary Reserve	12 Months Ended
	Jun. 30, 2014
Statuary Reserve [Abstract]	'
Statuary Reserve	'
	Note 13 – Statuary Reserve
	In accordance with the Companies Law of PRC, the Company is required to transfer 10% of its profit after tax, as determined in accordance with accounting standards and regulations of the PRC, to the statutory surplus reserve. The statutory surplus reserve is non-distributable. The Company transferred $129,097 and $727,172 to statutory reserve during the year ended June 30, 2014 and 2013.

Employee_Welfare_Plan

Employee Welfare Plan	12 Months Ended
	Jun. 30, 2014
Employee Welfare Plan [Abstract]	'
EMPLOYEE WELFARE PLAN	'
	Note 14 – Employee Welfare Plan
	The Company has established an employee welfare plan in accordance with Chinese laws and regulations. Full-time employees of the Group in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance and other welfare benefits are provided to employees. PRC labor regulations require the Group to accrue for these benefits based on a certain percentage of the employees’ salaries. The total contribution for such employee benefits was $942,452 and $867,175 for the fiscal years ended June 30, 2014 and 2013, respectively.

Risk_Factors

Risk Factors	12 Months Ended
	Jun. 30, 2014
Risk Factors [Abstract]	'
RISK FACTORS	'
	Note 15 – Risk Factors
	The Company's operations are carried out in the PRC. Accordingly, the Company's business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC as well as by the general state of the PRC’s economy. The Company's business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Risk_of_Concentrations_and_Cre

Risk of Concentrations and Credit Risk	12 Months Ended
	Jun. 30, 2014
Risk of Concentrations and Credit Risk [Abstract]	'
RISK OF CONCENTRATIONS AND CREDIT RISK	'
	Note 16 – Risk of Concentrations and Credit Risk
	Concentrations
	For the years ended June 30, 2014 and 2013, no single customer accounted for more than 10% of the Company’s sales. In terms of individual product sales, our major product Gingko Mihuan Oral Liquid (GMOL) contributes 47% or $22 million of total annual sales of fiscal year 2014 compared with GMOL’s contribution of 39% of total annual sales or $26.1 million from fiscal year 2013. No other products achieve more than 10% contribution for both fiscal years.
	For the fiscal years ended June 30, 2014, two major vendors accounted for approximately 25% or $3.9 million and 13% or $2.0 million, respectively, of the Company’s total inventory purchases. For the fiscal years ended June 30, 2013, three major vendors accounted for approximately 18% or $4.0 million, 14% or $3.2 million and 14% or $3.1 million, respectively, of the Company’s total inventory purchases.
	Credit Risk
	Financial instruments, which potentially subject the Company to credit risk consist principally of cash on deposit with financial institutions. Management believes that the financial institutions that hold the Company’s cash and cash equivalents are financially sound and minimal credit risk exists with respect to these investments.

Other_Expenses

Other Expenses	12 Months Ended
	Jun. 30, 2014
Other Expense [Abstract]	'
Other Expenses	'
	Note 17 – Other Expenses
	Other expenses represented penalty fees charged by CFDA resulting from their inspection in 2014.

Subsequent_Event

Subsequent Event	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENT	'
	Note 18 - SUBSEQUENT EVENT
	On September 30, 2014, the Company’s subsidiary, Chengdu Tianyin, acquired the remaining 13% of the JCM for RMB 15 million (approximately $2.4 million). Total payment of RMB 15 million was made on October 8, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America. The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
	Certain prior year amounts were reclassified to conform with current year presentation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include valuation reserves for accounts receivable, inventory, estimated useful life and residual value of property, plant and equipment, recognition and measurement of deferred income tax and valuation allowance for deferred tax assets. Although these estimates are based on management’s knowledge of current events and actions management may undertake in the future, actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with original maturities of three months or less to be “cash equivalents”.
Restricted Cash	'
	Restricted Cash
	Restricted cash consists of cash equivalents used as collateral to secure short-term notes payable.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are recognized and carried at the original invoice amount less an allowance for any uncollectible amount. We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for potential bad debts if required.
	We determine whether an allowance for doubtful accounts is required by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also record a general allowance as necessary
	Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.
	The Company has not experienced any significant difficulty in collecting its accounts receivable in the past and is not aware of any financial difficulties being experienced by its major customers.
Inventory	'
	Inventory
	Inventories consist of raw materials, packaging materials (which include ingredients and supplies) and finished goods. Inventory is stated at the lower of cost or market. Cost is determined using the weighted-average cost method. Provisions are made for excess, slow moving and obsolete inventory as well as inventory whose carrying value is in excess of net realizable value. Management continually evaluates the recoverability based on assumptions about customer demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory reserves or write-downs may be required that could negatively impact the Company’s gross margin and operating results. Inventory markdown allowance of $79,748 and zero were recorded at June 30, 2014 and 2013. Obsolete inventory of $1,447,735 and $159,123 were written-off in the year ended June 30, 2014 and 2013, respectively.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets as follows:
	Vehicles		5 to 10 years
	Furniture, machinery and equipment		5 to 10 years
	Buildings and improvements		10 to 50 years
	Construction in progress primarily represents the renovation costs of plant, machinery and equipment and stated at cost less any accumulated impairment loss. Costs incurred are capitalized and transferred to property and equipment upon completion, at which time depreciation commences.
	Cost of repairs and maintenance is expensed as incurred. Gain or loss on disposal of property and equipment, if any, is recognized in the consolidated statements of operations.
Impairment of Long-lived Assets	'
	Impairment of Long-lived Assets
	In accordance with ASC Topic 360-10-35 “Accounting for the Impairment or Disposal of Long-Lived Assets,”, long-lived assets, such as property, plant and equipment and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable, or it is reasonably possible that these assets could become impaired as a result of technological or other industrial changes. The determination of recoverability of assets to be held and used is made by comparing the carrying amount of an asset to future undiscounted cash flows to be generated by the assets. The Company reviews the recoverability of its long-lived assets on a periodic basis in order to identify business conditions, which may indicate a possible impairment. The assessment for potential impairment is based primarily on the Company’s ability to recover the carrying value of its long-lived assets from expected future undiscounted cash flows. If the total of the expected future undiscounted cash flows is less than the total carrying value of the assets, a loss is recognized for the difference between the fair value (computed based upon the expected future discounted cash flows) and the carrying value of the assets.
Intangible Assets	'
	Intangible Assets
	Intangible assets comprised of approved drugs and rights to use land. Intangible asset is carried at cost, less related accumulated amortization. Approved drugs are separated into two groups: Traditional Chinese Medicine (TCM) and Non Traditional Chinese Medicine (NTCM). TCM which has an indefinite life are not being amortized and are subject to impairment test at least annually to determine if the carrying value of the asset is impaired. NTCM drugs are amortized on a straight-line basis over their estimated useful life of 10 years.
	Rights to use land with a finite useful life is being amortized on a straight line basis over its estimated useful life of 48 years.
Goodwill	'
	Goodwill
	The Company accounts for business acquisitions in accordance with ASC 805-10, which may result in the recognition of goodwill. Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations accounted for under the purchase method.
	Goodwill is not subject to amortization but will be subject to periodic evaluation for impairment. Goodwill is stated in the consolidated balance sheet at cost less accumulated impairment loss, if any. The Company reviews its goodwill for impairment annually or more frequently if indicators of impairment exist. The Company adopted an accounting standard update, commonly referred to as the step zero approach that allows it to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. For reporting units in which the qualitative assessment concludes it is more likely than not that the fair value is more than its carrying value, the amended guidance eliminates the requirement to perform further goodwill impairment test. For those reporting units where a significant change or event occurs, and where potential impairment indicators exist, the Company continues to utilize a two-step quantitative assessment to testing goodwill for impairment. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others (a) a significant decline in expected future cash flows; (b) a sustained, significant decline in stock price and market capitalization; (c) a significant adverse change in legal factors or in the business climate; (d) unanticipated competition; (e) the testing for recoverability of a significant asset group within a reporting unit; and (f) slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of these assets and could have a material impact on the consolidated financial statements. The goodwill test impairment consists of two steps. First, the identification of potential impairment is performed by comparing the fair value of the reporting unit to its carrying amount, including goodwill. Second, if there is impairment identified in the first step, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of goodwill. The Company has assessed its goodwill for impairment for the periods presented. There are no impairment charges related to goodwill for any of the fiscal periods presented.
Impairment of Intangible Assets	'
	Impairment of Intangible Assets
	The Company applies the provisions of ASC Topic 350 which addresses how goodwill and other acquired intangible assets should be accounted for in financial statements. In this regard, the Company tests these intangible assets for impairment annually or more frequently if indicators of potential impairment are present. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value.
	The fair value is measured based on quoted market prices, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the year ended June 30, 2014, the Company applied a benchmark borrowing interest rate of 7.0% as the discount rate and recorded the impairment loss of $-0- related to intangible assets for the years ended June 30, 2014 and 2013, respectively.
Revenue Recognition	'
	Revenue Recognition
	The Company derives its revenues primarily from sale of pharmaceutical products. In accordance with ASC Topic 605 “Revenue Recognition”, revenue should not be recognized until it is realized or realizable and earned. Revenues are considered to have been earned when the entity has substantially accomplished what it must do to be entitled to the benefits represented by the revenues. In this regard, the Company’s revenue is recognized when merchandise is received by customers or shipped by the Company pursuant to contractual terms of sales, title and risk of loss passes to the customers, sales amounts are fixed and determinable and the collectability is reasonably assured.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	Shipping and handling costs billed to customers in related sales transactions are included in sales revenues and shipping expenses incurred by the Company are reported as a component of selling expenses. The shipping and handling expenses of $615,925 and $1,307,921 for the year ended June 30, 2014 and 2013, respectively, are reported in the Consolidated Statements of Operations as a component of selling expenses.
Research and Development	'
	Research and Development
	Research and development costs are expensed when incurred. Research and development costs for the years ended June 30, 2014 and 2013 were $949,300 and $894,995, respectively.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	A valuation allowance is provided to reduce the carrying amount of deferred tax assets if it is considered more likely than not that some portion, or all, of the deferred tax assets will not be realized.
Value Added Taxes	'
	Value Added Taxes
	Under the Provisional Regulations of the PRC on Value Added Tax, the Company is responsible for collecting value added taxes on sales of products and to pay value added taxes on purchases of raw materials, which is then remitted to the central government. Sales and cost of sales are reported on a net basis excluding value added taxes.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments include cash equivalents, accounts receivable, notes receivable, accounts payable, short-term debt and other financial instruments associated with the issuance of the common stock. The carrying values of cash equivalents, accounts receivable, notes receivable, and accounts payable approximate their fair value because of the short maturity of these instruments. The carrying amounts of the Company’s bank borrowings under its credit facility approximate fair value because the interest rates are reset periodically to reflect current market rates.
	The Company adopted ASC 820-10, “Fair Value Measurements.” ASC 820-10, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1: Observable inputs such as quoted prices in active markets;
	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	We have no financial assets or liabilities measured at fair value on a recurring basis
Foreign Currency Translation and Transactions	'
	Foreign Currency Translation and Transactions
	The Company has evaluated the determination of its functional currency based on the guidance in ASC Topic, “Foreign Currency Matters,” which provides that an entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment in which an entity primarily generates and expends cash.
	On its own, the Company raises financing in the U.S. Dollar, pays its own operating expenses primarily in the U.S. Dollar, paid dividends to its shareholders of common stock and expects to receive any dividends that may be declared by its subsidiaries in U.S. dollars.
	Therefore, it has been determined that the Company’s functional currency is the U.S. dollar based on the expense and financing indicators, in accordance with the guidance in ASC 830-10-85-5.
	The Company uses the United States dollar (“U.S. Dollar” or “US$” or “$”) for financial reporting purposes. The subsidiaries within the Company maintain their books and records in their respective functional currency, being the primary currency of the economic environment in which their operations are conducted. Assets and liabilities of a subsidiary with functional currency other than U.S. Dollar are translated into U.S. Dollars using the applicable exchange rates prevailing at the balance sheet date. Items on the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the Company’s financial statements are recorded as accumulated other comprehensive income.
	The exchange rates used to translate amounts in RMB into US Dollars for the purposes of preparing the condensed combined financial statements were as follows:
				June 30,	June 30,
				2014	2013
		Balance sheet items, except for shareholders’ equity items		RMB 1: US$0.1624	RMB 1: US$0.16200
		Amounts included in the statements of operations, comprehensive income, and cash flows for the years then ended		RMB 1: US$0.1627	RMB 1: US$0. 15945
		Shareholders’ equity items		Historical rate	Historical rate
Comprehensive Income	'
	Comprehensive Income
	The Company has adopted ASC Topic 220-10, Reporting Comprehensive Income, which establishes rules for the reporting and display of comprehensive income, its components and accumulated balances. ASC 220-10 defines comprehensive income to include all changes in equity, including adjustments to minimum pension liabilities, accumulated foreign currency translation, and unrealized gains or losses on available-for-sale marketable securities, except those resulting from investments by stockholders and distributions to stockholders. Comprehensive income includes net income and the foreign currency translation gain, net of tax.
Share-Based Payment	'
	Share-Based Payment
	The Company recognizes compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, the fair value of the award on the date of grant is calculated in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
Earnings Per Share	'
	Earnings Per Share
	In accordance with ASC 260, “Computation of Earnings Per Share” and EITF No. 03-6, “Participating Securities and the Two-Class Method under FASB Statement No. 128” (“EITF No. 03-6”), basic earnings per share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. The Company’s Series A redeemable convertible preferred shares are participating securities. Diluted earnings per share is calculated by dividing net income attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the year. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the convertible preferred shares (using the if-converted method) and ordinary shares issuable upon the exercise of outstanding share options (using the treasury stock method).
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In April 2014, the FASB issued amendments to ASC Topic 205 “Presentation of Financial Statements” and ASC Topic 360 “Property, Plant and Equipment”. The amendments change the current requirements for reporting discontinued operations in Subtopic 205-20. It requires an entity to present, for each comparative period, the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability section, respectively, of the statement of financial position. This topic is effective for public entities for reporting periods beginning after December 15, 2014. An entity should not apply the amendments to a component classified as held for sale before the effective date even if the component of an entity is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company does not believe the adoption of the amendments to ASC 205 and ASC 360 will have a material effect on its consolidated financial statements.
	There are no other new accounting pronouncements adopted or enacted during the year ended June 30, 2014 that had, or are expected to have, a material impact on the Company’s financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Schedule of property and equipment estimated useful lives	'
	Vehicles		5 to 10 years
	Furniture, machinery and equipment		5 to 10 years
	Buildings and improvements		10 to 50 years
Schedule of exchange rates used to translate amounts for the purposes of preparing the condensed combined financial statements	'
				30-Jun-14	30-Jun-13
		Balance sheet items, except for shareholders’ equity items		RMB 1: US$0.1624	RMB 1: US$0.16200
		Amounts included in the statements of operations, comprehensive income, and cash flows for the years then ended		RMB 1: US$0.1627	RMB 1: US$0. 15945
		Shareholders’ equity items		Historical rate	Historical rate

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Jun. 30, 2014
Inventory [Abstract]	'
Schedule of inventory	'
			June 30,		June 30,
			2014		2013
		Raw materials	$	690,355	$	748,296
		Packaging supplies		387,599		369,143
		Work in process		1,088,880		1,871,093
		Finished goods		1,674,878		3,047,482
		Total	$	3,841,712	$	6,036,014

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2014
Property and Equipment [Abstract]	'
Schedule of property and equipment	'
			June 30,		June 30,
			2014		2013
		Buildings	$	15,188,962	$	15,151,551
		Machinery and equipment		14,588,168		14,552,237
		Office equipment and furniture		102,236		101,984
		Vehicles		69,508		69,337
		Subtotal		29,948,874		29,875,109
		Less: Accumulated depreciation		7,127,561		5,350,377
				22,821,313		24,524,732
		Add: Construction in progress		22,557,043		16,078,500
		Total	$	45,378,356	$	40,603,232

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2014
Intangible Assets and Goodwill [Abstract]	'
Schedule of intangible assets	'
			June 30,		June 30,
			2014		2013
		Rights to use land	$	14,770,400	$	7,790,720
		Approved drugs		17,060,652		17,018,631
		Intangible assets		31,831,052		24,809,351
		Less: accumulated amortization		4,131,319		3,304,339
		Total	$	27,699,733	$	21,505,012

Loan_Receivable_Tables

Loan Receivable (Tables)	12 Months Ended
	Jun. 30, 2014
Loan Receivables [Abstract]	'
Schedule of Loan recievable	'
		Loan to an individual and guaranteed by a third party, collateralized by third party's machinery and equipment, bear interest at 50% above the bank standard rate and due on September 16, 2014. The loan was fully collected in September 19, 2014	$	812,000
		Loan to an unrelated company, bear interest at 50% above the bank standard rate and due on September 8, 2014. The loan was collateralized by the machinery and equipment of the company. The loan was fully collected in September 15, 2014.		1,169,280
		Total	$	1,981,280

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable and accrued expenses	'
			June 30,		June 30,
			2014		2013
		Accounts payable	$	1,476,830	$	1,206,760
		Accrued expenses		115,629		145,800
		Total	$	1,592,459	$	1,352,560

Accounts_Payable_Construction_1

Accounts Payable - Construction Related (Tables)	12 Months Ended
	Jun. 30, 2014
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable - construction related	'
			June 30,		June 30,
			2014		2013
		Construction in progress payable	$	2,238,927	$	1,822,500
		Land use rights payable		-		900,790
		Total	$	2,238,927	$	2,723,790

ShortTerm_Bank_Loans_Tables

Short-Term Bank Loans (Tables)	12 Months Ended
	Jun. 30, 2014
Short-Term Bank Loans [Abstract]	'
Schedule of short-term bank loans	'
			June 30,		June 30,
			2014		2013
		On September 19, 2012, the Company obtained a loan from China Huaxia Bank, the principal balance was paid in full on September 27, 2013. The interest is calculated using an annual fixed interest rate of 7.257% and paid monthly. The loan was guaranteed by a third party and the Company’s CEO, Dr. Jiang.		-	$	1,620,000
		On June 21, 2013, the Company obtained a loan from China CITIC Bank, which matures on December 21, 2013. The interest is calculated using an annual fixed interest rate of 6.44% and paid monthly. The loan was secured by the Company’s certificates of deposit, which included in the restricted cash on the Company’s balance sheet. The loan was paid in full in December 2013.		-	$	4,309,200
		On October 30, 2013, the Company obtained a loan from China CITIC Bank, which matures on October 30, 2014. The interest is calculated using an annual fixed interest rate of 7.20% and paid monthly. The loan was guaranteed by the Company’s CEO, Dr. Jiang.	$	4,547,200		-
		Total short-term bank loans	$	4,547,200	$	5,929,200

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Summary of comparison of income tax expense	'
			Fiscal Years ended
			June 30,
			2014			2013
		U.S. Statutory rate of 35%	$	(214,460	)	$	3,163,678
		Tax rate difference between China and U.S.		76,080			(903,778	)
		Change in valuation allowance		333,705			164,007
		Effective tax	$	195,325		$	2,423,907
Summary of provisions for income taxes	'
			Fiscal Years ended
			June 30,
			2014			2013
		Current	$	1,375,835		$	2,423,907
		Deferred		(1,678,222	)		(164,007	)
		Valuation allowance		497,712			164,007
		Total	$	195,325		$	2,423,907
Schedule of net deferred tax asset	'
			June 30,			June 30,
			2014			2013
		Net operating loss carryforward	$	1,607,835		$	164,007
		Inventory markdown		19,937			-
		Accrued expenses		31,420			-
		Others		19,030			-
				1,678,222			164,007
		Less valuation allowance		(497,712	)		(164,007	)
		Deferred tax assets		1,180,510			-

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details) (Chengdu Tianyin Pharmaceutical Co., Ltd. [Member])	1 Months Ended
	Aug. 29, 2012	Aug. 29, 2012	Jun. 30, 2014
	USD ($)	CNY	USD ($)
	shareholder
Organization and Nature of Business (Textual)	'	'	'
Number of existing shareholders entered into share transfer agreement with the company	2	2	'
Ownership percentage owned	100.00%	100.00%	'
Total purchase consideration of acquired entity	$210,600	1,300,000	'
Purchase price allocated to goodwill	'	'	$210,600

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2014
Vehicles [Member]	'
Schedule of property and equipment estimated useful life	'
Estimated useful lives	'5 to 10 years
Furniture, machinery and equipment [Member]	'
Schedule of property and equipment estimated useful life	'
Estimated useful lives	'5 to 10 years
Buildings and improvements [Member]	'
Schedule of property and equipment estimated useful life	'
Estimated useful lives	'10 to 50 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013
	USD ($)	CNY	USD ($)	CNY
Multiple Foreign Currency Exchange Rates [Abstract]	'	'	'	'
Balance sheet items, except for shareholders' equity items	$0.16	1	$0.16	1
Amounts included in the statements of operations, comprehensive income, and cash flows for the years then ended	$0.16	1	$0.16	1
Shareholders' equity items	'Historical rate	'Historical rate	'Historical rate	'Historical rate

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Summary of Significant Accounting Policies (Textual)	'	'
Maturity period description of highly liquid instruments	'Three months or less	'
Estimated useful life of drugs	'10 years	'
Estimated useful life of rights to use land	'48 years	'
Research and development	$946,300	$894,995
Borrowing interest rate	7.00%	'
Impairment loss related to intangible assets	0	0
Deferred tax assets	0	0
Deferred tax liabilities	0	0
Shipping and handling expenses	615,925	1,307,921
Inventory markdown allowance	79,748	0
Inventory Write-down	$1,527,483	$159,123

Inventory_Details

Inventory (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Schedule of inventory	'	'
Raw materials	$690,355	$748,296
Packaging supplies	387,599	369,143
Work in process	1,088,880	1,871,093
Finished goods	1,674,878	3,047,482
Total	$3,841,712	$6,036,014

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Schedule of property and equipment	'	'
Buildings	$15,188,962	$15,151,551
Machinery and equipment	14,588,168	14,552,237
Office equipment and furniture	102,236	101,984
Vehicles	69,508	69,337
Subtotal	29,948,874	29,875,109
Less: Accumulated depreciation	7,127,561	5,350,377
Property and equipment excluding construction in progress	22,821,313	24,524,732
Add: Construction in progress	22,557,043	16,078,500
Total	$45,378,356	$40,603,232

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Property and Equipment (Textual)	'	'
Depreciation expense	$1,767,232	$1,631,191

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Schedule of intangible assets	'	'
Rights to use land	$14,770,400	$7,790,720
Approved drugs	17,060,652	17,018,631
Intangible assets	31,831,052	24,809,351
Less: accumulated amortization	4,131,319	3,304,339
Total	$27,699,733	$21,505,012

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Intangible Assets (Textual)	'	'
Amortization expense of intangible assets	$820,333	$803,947

Goodwill_Details

Goodwill (Details) (Chengdu Tianyin Pharmaceutical Co., Ltd. [Member])	1 Months Ended
	Aug. 29, 2012	Aug. 29, 2012	Jun. 30, 2014
	USD ($)	CNY	USD ($)
Goodwill (Textual)	'	'	'
Ownership percentage owned	100.00%	100.00%	'
Total purchase consideration of acquired entity	$210,600	1,300,000	'
Purchase price allocated to goodwill	'	'	$210,600

Loan_Receivable_Details

Loan Receivable (Details) (USD $)	Jun. 30, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Loan Receivable, Net	$1,981,280
Related to third party	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Loan Receivable, Net	812,000
Unrelated company	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Loan Receivable, Net	$1,169,280

Loan_Receivable_Details_Textua

Loan Receivable (Details Textual)	12 Months Ended
	Jun. 30, 2014
Related to third party	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Loans and Leases Receivable, Description	'Collateralized by third party's machinery and equipment, bear interest at 50% above the bank standard rate and due on September 16, 2014. The loan was fully collected in September 19, 2014
Bank bear interest rate	50.00%
Unrelated company	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'
Loans and Leases Receivable, Description	'Bear interest at 50% above the bank standard rate and due on September 8, 2014. The loan was collateralized by the machinery and equipment of the company. The loan was fully collected in September 15, 2014.
Bank bear interest rate	50.00%

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Accounts payable and accrued expenses	'	'
Accounts payable	$1,476,830	$1,206,760
Accrued expenses	115,629	145,800
Total	$1,592,459	$1,352,560

Accounts_Payable_Construction_2

Accounts Payable - Construction Related (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Total	$2,238,927	$2,723,790
Land use right payable [Member]	'	'
Total	'	900,790
Construction in progress payable [Member]	'	'
Total	$2,238,927	$1,822,500

ShortTerm_Bank_Loans_Details

Short-Term Bank Loans (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Schedule of short-term bank loans	'	'
Total short-term bank loans	$4,547,200	$5,929,200
Fixed interest rate of 7.257% [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	'	1,620,000
Fixed interest rate of 6.44% [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	'	4,309,200
Fixed interest rate of 7.20% [Member]	'	'
Schedule of short-term bank loans	'	'
Total short-term bank loans	$4,547,200	'

ShortTerm_Bank_Loans_Details_T

Short-Term Bank Loans (Details Textual)	1 Months Ended		0 Months Ended
	Sep. 19, 2012	Jun. 21, 2013	Oct. 30, 2013
	Fixed interest rate of 7.257% [Member]	Fixed interest rate of 6.44% [Member]	Fixed interest rate of 7.20% [Member]
Short-Term Bank Loans (Textual)	'	'	'
Annual fixed interest rate of short-term bank loans	7.26%	6.44%	7.20%
Maturity date	27-Sep-13	21-Dec-13	30-Oct-14

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'
U.S. Statutory rate of 35%	($214,460)	$3,163,678
Tax rate difference between China and U.S.	76,080	-903,778
Change in valuation allowance	333,705	164,007
Effective tax	$195,325	$2,423,906

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'
Current	$1,375,835	$2,423,907
Deferred	-1,678,222	-164,007
Valuation allowance	497,712	164,007
Total	$195,325	$2,423,906

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Abstract]	'	'
Net operating loss carryforward	$1,607,835	$164,007
Inventory markdown	19,937	'
Accrued expenses	31,420	'
Others	19,030	'
Deferred tax assets, Gross	1,678,222	164,007
Less valuation allowance	-497,712	-164,007
Deferred tax assets	$1,180,510	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes (Textual)	'	'
Effective tax rates	35.00%	35.00%
Chengdu Tianyin Medicine Trading Co., Ltd. [Member]	'	'
Income Taxes (Textual)	'	'
Effective tax rates	25.00%	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stockholders' Equity [Line Items]	'	'
Share-based payment	$55,000	$30,000
Common Stock [Member]	'	'
Stockholders' Equity [Line Items]	'	'
Common shares issued, Shares	50,000	50,000

Statuary_Reserve_Details

Statuary Reserve (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Statuary Reserve (Textual)	'	'
Percentage of statutory surplus reserve	10.00%	'
Statutory reserve transferred	$129,097	$727,172

Employee_Welfare_Plan_Details

Employee Welfare Plan (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Employee Welfare Plan (Textual)	'	'
Employer contribution in employee welfare plan	$942,452	$867,175

Risk_of_Concentrations_and_Cre1

Risk of Concentrations and Credit Risk (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
	Vendor	Vendor
Risk of Concentrations and Credit Risk (Textual)	'	'
Number of vendor	2	3
Sales [Member] | GMOL [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	10.00%	10.00%
Sales [Member] | Customer [Member] | GMOL [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	47.00%	39.00%
Major sales from customer	22	26.1
Purchase One [Member] | Vendor One [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	25.00%	18.00%
Total purchase from major vendors	3.9	4
Purchaser Two [Member] | Vendor Two [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	13.00%	14.00%
Total purchase from major vendors	2	3.2
Purchaser Three [Member] | Vendor Three [Member]	'	'
Risk of Concentrations and Credit Risk (Textual)	'	'
Concentration risk, percentage	'	14.00%
Total purchase from major vendors	'	3.1

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], Chengdu Tianyin [Member])	0 Months Ended	1 Months Ended
	Oct. 08, 2014	Sep. 30, 2014	Sep. 30, 2014
	CNY	USD ($)	CNY
Subsequent Event [Line Items]	'	'	'
Business acquisition, Percentage of interest	'	13.00%	13.00%
Business acquired the remaining, Value	'	$2,400,000	15,000,000
Payments to acquire business	15,000,000	'	'